193 related articles for article (PubMed ID: 21505581)
1. Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.
Vladareanu AM; Popov V; Bumbea H; Onisai M; Ilea A; Dobrea C; Miulescu M
J Med Life; 2011; 4(1):97-101. PubMed ID: 21505581
[TBL] [Abstract][Full Text] [Related]
2. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
De Stefano V; Teofili L; Leone G; Michiels JJ
Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
Kiladjian JJ; Cassinat B
Am J Hematol; 2023 May; 98(5):794-800. PubMed ID: 36869873
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
10. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract][Full Text] [Related]
11. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
Fan J; Wang Q; Luo B; Chen H; Wang Z; Niu J; Yuan J; Yuan X; Bai W; He C; Guo W; Li K; Yin Z; Fan D; Han G
J Gastroenterol Hepatol; 2020 Jul; 35(7):1215-1222. PubMed ID: 31711259
[TBL] [Abstract][Full Text] [Related]
13. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
Janssen HL; Leebeek FW
Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
[No Abstract] [Full Text] [Related]
14. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases.
Lavu S; Szuber N; Mudireddy M; Yogarajah M; Gangat N; Pardanani A; Hanson CA; Ketterling RP; Ashrani AA; Kamath PS; Tefferi A
Am J Hematol; 2018 Mar; 93(3):E61-E64. PubMed ID: 29194707
[No Abstract] [Full Text] [Related]
15. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
16. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative diseases as causative agents of portal and hepatic veins thrombosis].
Culafić Dj; Miljić P; Perisić M; Djuranović S; Popović D; Krstić M; Jovanović I; Pavlović A; Mijalković N; Sokić-Milutinović A; Pesko P
Acta Chir Iugosl; 2007; 54(1):83-9. PubMed ID: 17633867
[TBL] [Abstract][Full Text] [Related]
18. Non conventional mutations associated with myeloproliferative disorders are absent in splanchnic venous thrombosis cases.
Jadli A; Kulkarni B; Ghosh K; Shetty S
Liver Int; 2012 Nov; 32(10):1596-7. PubMed ID: 22816981
[No Abstract] [Full Text] [Related]
19. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]